Tesamorelin (5mg & 10mg)

Tesamorelin and Growth Hormone Regulation

Tesamorelin, a synthetic polypeptide containing 44 amino acids, shares structural similarities with growth hormone-releasing hormone (GHRH), crucial in growth hormone regulation. Notably, Tesamorelin incorporates modifications at the N-terminus, a feature believed by researchers to enhance stability compared to natural GHRH.

Tesamorelin has been the subject of investigation concerning its potential mechanism, believed to parallel the receptors of growth hormone-releasing hormones (GHRH) situated at the anterior pituitary gland. This purported similarity might contribute to an augmentation in the synthesis and release of growth hormones. The consequential impact of growth hormones extends to various cell types, with hepatocytes being a notable target, potentially triggering the synthesis of insulin-like growth factor-1 (IGF-1).

Overview

Similar to its counterpart GH, insulin-like growth factor-1 (IGF-1) has been theorized to have potential effects such as growth stimulation, inhibition of programmed cell death, glucose reduction, and lipolysis. Lipodystrophy models displaying reduced GH and IGF-1 levels have been a focus of investigation. Researchers exploring the actions of Tesamorelin propose that this peptide may exert a beneficial influence on lipid metabolism.

Tesamorelin exhibits a modified N-terminus in its GHRH molecule, a feature that may confer stability to the peptide. This alteration could potentially enhance the compound’s resilience against enzyme deactivation, distinguishing it from natural GHRH.

Exploration and Scientific Investigations

Tesamorelin Peptide and Immunodeficiency

Exploring the potential impact of Tesamorelin on individuals with immunodeficiencies, a clinical study was conducted involving 806 test subjects over a span of 26 weeks, followed by a 26-week extension. The subjects, all having immunodeficiencies, were divided into two groups – one receiving Tesamorelin and the other a placebo for the initial 26 weeks. Subsequently, the Tesamorelin group was further randomized, with half continuing the peptide and the other receiving a placebo for an additional 26 weeks. At the 26-week mark, researchers observed a significant reduction (at least 15.4%) in visceral adipose tissue levels in the Tesamorelin group compared to the placebo. Additionally, Tesamorelin appeared to contribute to decreased triglyceride and cholesterol levels in comparison to the placebo group.

Tesamorelin Peptide and Hepatic Fat Fraction in Immunodeficiency

Examining the impact of Tesamorelin on individuals with immunodeficiency-related complications, a study focused on 61 subjects with HIV and elevated hepatic fat fraction (HFF). In clinical settings, serious immunodeficiencies, especially in HIV-positive individuals, are associated with a higher risk of non-alcoholic fatty liver disease (NAFLD). The selected subjects were administered Tesamorelin or a placebo over a 12-month period, with HFF rates monitored throughout the trial. After completion, researchers observed a notable reduction in HFF rates (less than 5%) in 35% of subjects receiving Tesamorelin, compared to a mere 4% in the placebo group. Notably, glucose levels remained unchanged in both groups.

Tesamorelin Peptide and Neurological Function in Immunodeficiency

Exploring the potential impact of Tesamorelin on cognitive function, a clinical study focused on immunodeficient subjects with mild cognitive impairment. The trial involved 100 participants aged over 40, who received daily Tesamorelin administration for a 6-month period. Subsequently, there was a 6-month period without Tesamorelin influence, followed by a re-introduction of Tesamorelin once a day for another 6 months. The primary outcome measure centered on changes in neurocognitive performance, assessed through the Global Deficit Score (GDS) at the 6 and 12-month marks. Currently ongoing, the study aims to shed light on the potential impact of Tesamorelin on neurological functioning in individuals with immunodeficiency.

Tesamorelin Peptide and Cardiovascular Health

Exploring the potential impact of Tesamorelin on cardiovascular health, a clinical study focused on 53 participants with Type II diabetes in a 12-week randomized trial. The subjects were divided into three groups, each receiving varying concentrations of Tesamorelin or a placebo. After the 12-week study period, parameters such as fasting glucose, glycosylated hemoglobin, and diabetes control were assessed. The study results indicated no significant reduction in these parameters across all three groups, suggesting that Tesamorelin did not exhibit a notable effect on insulin sensitivity in individuals with Type II diabetes.

Tesamorelin peptide is exclusively intended for research and laboratory applications. Prior to placing an order, kindly review and comply with the Terms and Conditions outlined on our platform.